DNMT3A and prostate carcinoma: Previous studies suggested that DNMT3A was overexpressed in various tumors, such as prostate cancer (Patra et al, 2002), breast cancer (Girault et al, 2003) and PC (He et al, 2011), which was consistent with our findings.